arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Bone Biologics Corp

BBLG
$0.35 ▼ -0.02 (-5.34%) at close
Healthcare ·Orthopedic, Prosthetic & Surgical Appliances & Supplies ·USOrthopedic, Prosthetic & Surgical Appliances & Supplies
79 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Bone Biologics Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -8.8% ↗
FCF / Share $-0.14 ↗
Trailing P/E —
Price / Book 0.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 4, 2026.

79-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-765.99K
↑ +24.7% —
Operating Margin Operating profit as % of sales
-0.0%
↑ +46.8% —
FCF / Share Free cash flow per share
$-0.14
↑ +50.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Cash Quality ↑
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 19 years · 79 quarters